Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406952 | 0.87 | PTGS2 (0.43) | PTGS1PTGS2LMNAMAPT | |
| SCHEMBL6407339 | 0.87 | PTGS2 (0.43) | PTGS1PTGS2LMNAMAPT | |
| SCHEMBL6404963 | 0.81 | PTGS1 (0.38) | PTGS1PTGS2 | |
| SCHEMBL6404958 | 0.72 | PTGS1 (0.34) | PTGS1PTGS2 | |
| SCHEMBL6404569 | 0.72 | PTGS2 (0.43) | PTGS1PTGS2AKR1B1LMNAMAPT | |
| SCHEMBL6405275 | 0.72 | PTGS2 (0.43) | PTGS1PTGS2AKR1B1LMNAMAPT | |
| SCHEMBL6409687 | 0.72 | PTGS2 (0.43) | PTGS1PTGS2AKR1B1 | |
| SCHEMBL6405761 | 0.72 | PTGS2 (0.43) | PTGS1PTGS2AKR1B1 | |
| SCHEMBL6680241 | 0.72 | PTGS2 (0.41) | PTGS1PTGS2 | |
| SCHEMBL6407729 | 0.69 | PTGS2 (0.42) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050010050-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2-mediated disorders | G.D. SEARLE & CO. (US) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050010050-A1 | Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2-mediated disorders | PTGS2, PTGES2, PTGER2 | PTGS1 5/4885PTGS2 1/4885AKR1B1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.